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We investigated the use of purinergic receptors as a new treatment modality for nonmelanoma skin cancers. Purinergic receptors, which bind adenosine 5 0 -triphosphate, are expressed on human cutaneous keratinocytes. Previous work in rat and human epidermis suggested functional roles for purinergic receptors in the regulation of proliferation, di¡erentiation, and apoptosis. Immunohistochemical analysis of frozen sections in human basal cell carcinomas and squamous cell carcinomas for P2X 5 , P2X 7 , P2Y 1 , P2Y 2 , and P2Y 4 receptors was performed, accompanied by detailed analysis of archive material of tumor subtypes in para⁄n sections. Functional studies were performed using a human cutaneous squamous cell carcinoma cell line (A431), where purinergic receptor subtype agonists were applied to cells and changes in cell number were quanti¢ed via a colorimetric assay. Immunostaining in para⁄n sections was essentially the same as that in frozen sections, although more detail of the subcellular composition was visible. P2X 5 and P2Y 2 receptors were heavily expressed in basal cell carcinomas and squamous cell carcinomas. P2X 7 receptors were expressed in the necrotic center of nodular basal cell carcinomas and in apoptotic cells in super¢cial multifocal and in¢ltrative basal cell carcinomas, and squamous cell carcinomas. P2Y 1 receptors were only expressed in the stroma surrounding tumors. P2Y 4 receptors were found in basal cell carcinomas but not in squamous cell carcinomas. P2X 5 receptors appear to be associated with di¡erentiation. The P2X 7 receptor agonist benzoylbenzoyl-adenosine 5 0 -triphosphate and high concentrations of adenosine 5 0 -triphosphate (1000^5000 lM) caused a signi¢cant reduction in A431 cell number (po0.001), whereas the P2Y 2 receptor agonist uridine 5 0 -triphosphate caused a signi¢cant amount of proliferation (po0.001). We have demonstrated that non-melanoma skin cancers express functional purinergic receptors and that P2X 7 receptor agonists signi¢cantly reduce cell numbers in vitro. Key words: adenosine triphosphate/apoptosis/basal cell/carcinoma/ carcinoma/purinergic P2/receptors/squamous cell. J Invest Dermatol 121: 315^327, 2003 B asal cell carcinoma (BCC) and squamous cell carcinoma (SCC) of the skin are the commonest malignancies in White people, accounting for more than 95% of non-melanoma skin cancers (NMSC) (Miller and Weinstock, 1994) . The incidence of NMSC has risen signi¢cantly over the last 10 y (Holme et al, 2000) . An estimated 2.75 million cases of NMSC are diagnosed per year worldwide (Strom and Yamamura, 1997) , with approximately one million cases per year diagnosed in the USA (Miller and Weinstock, 1994) . Multiple treatment modalities are available for NMSC, and surgical management is the most common approach. In patients with multiple lesions or in cases of tumors on di⁄cult locations (e.g., eyelids or lips), surgery can cause signi¢cant dis¢gurement. Topical drug treatment is indicated for super¢cial cutaneous neoplasms, which because of their multiplicity and involvement of large surfaces are di⁄cult to treat with other methods. The purpose of this study was to investigate whether purinergic receptors could represent a suitable target for drug treatment of NMSC.
There is increasing evidence that purinergic signaling can have long-term, trophic e¡ects in embryonic development, cell growth, di¡erentiation, and proliferation (Abbracchio and Burnstock, 1998; Burnstock, 2001 Burnstock, , 2002 . Purinergic receptors are classi¢ed into two groups: P1 receptors are selective for adenosine and P2 receptors are selective for adenosine 5 0 -triphosphate (ATP) and adenosine 5 0 -diphosphate (ADP), which act as extracellular signaling molecules (Burnstock, 1978) . P2 receptors are divided into two main families: P2X and P2Y, based on molecular structure, transduction mechanisms and pharmacologic properties (Abbracchio and Burnstock, 1994 involves phospholipase C, which leads to the formation of inositol 1,4,5-triphosphate (IP 3 ) and mobilization of intracellular calcium. IP 3 regulates cell growth and DNA replication (Berridge, 1987) . Seven subtypes of P2Y receptors have been described so far (King et al, 2000; Communi et al, 2001) . In contrast, P2X receptors are ligand-gated ion channels, and are activated by extracellular ATP to elicit a £ow of cations (Na þ , K þ , and Ca 2 þ ) across the plasma membrane. Seven subtypes of P2X receptors are recognized (Khakh et al, 2001a) ; all P2X 1^7 subunits have been cloned from mammalian species and are capable of assembling into homomultimeric or heteromultimeric receptors (Torres et al, 1999) .
There is growing evidence that ATP may act as an important local messenger in the skin, particularly the epidermis. Purinergic receptors are expressed on rat cutaneous keratinocytes and functional roles in the regulation of proliferation, di¡erentiation, and cell death have been proposed (Gr˛schel-Stewart et al, 1999) . In particular, P2X 5 receptors are expressed on cells undergoing proliferation and di¡erentiation, whereas P2X 7 receptors are associated with keratinized dead cells. P2Y 2 receptors, found in the basal layer of normal epidermis, are claimed to be involved in keratinocyte proliferation (Dixon et al, 1999) . P2Y 1 receptors are thought to be mitogenic in endothelial cells and P2Y 2 and P2Y 4 receptors stimulate vascular smooth muscle cell proliferation (Burnstock, 2002) .
There is evidence that there are functional purinergic receptors in human malignant cell lines, including: MCF-7 breast cancer cells (Wagsta¡ et al, 2000) , endometrial cancer cell lines (Katzur et al, 1999) , prostate carcinoma cells (Janssens and Boeynaems, 2001) , colorectal carcinoma cells (H˛pfner et al, 1998) , ovarian cancer cells (Schultze-Mogasu et al, 2000) , and HL-60 leukemia cells (Conigrave et al, 2000) .
This study demonstrates the spatially distinct distribution patterns of di¡erent P2X and P2Y receptors in human BCC and SCC as well as evidence for the actions of purinergic agonists on cell proliferation and death in a SCC cell line. This suggests a pathophysiologic role for these receptors and raises the possibility that purinergic agonists are putative therapeutic agents.
MATERIALS AND METHODS
Tissues Frozen sections of 10 BCC (¢ve male, ¢ve female, mean age 71) and four SCC (two male, two female, mean age 73) were examined in this study. Ethics Committee Approval was obtained to harvest human NMSC samples from consenting patients. The di⁄culty of obtaining fresh human tissue for frozen sections led to the development of a special method to allow staining of P2X 5 and P2X 7 receptors in para⁄n sections. Para⁄n blocks of a BCC and SCC belonging to a collection at Mount Vernon Hospital were examined.
Tissue was frozen in isopentane precooled in liquid nitrogen. Blocks were sectioned at 10 mm on a cryostat (Reichert Jung CM1800), collected on gelatin-coated slides and air-dried at room temperature. The slides were stored at^201C.
Antibodies The immunogens used for production of polyclonal P2X 5 and P2X 7 antibodies were synthetic peptides corresponding to 15 receptor-type-speci¢c amino acids in the intracellular C-termini of the cloned rat and human P2X receptors, as described previously (Gr˛schel-Stewart et al, 1999 , Oglesby et al, 1999 . The polyclonal antibodies were raised by multiple monthly injections of New Zealand rabbits with the peptides (performed by Research Genetics, Huntsville, Alabama). P2X 5 and P2X 7 antibodies (provided by Roche Bioscience, Palo Alto, California) were kept frozen at a stock concentration of 1 mg per mL. Polyclonal anti-P2Y 1 , P2Y 2 , and P2Y 4 receptor antibodies were obtained from Alomone Laboratories (Jerusalem, Israel) , and corresponded to the third extracellular loop of the P2Y 1 (amino acids 242^258), P2Y 2 (amino acids 227^244), and P2Y 4 receptor (amino acids 337^350) and were also raised in rabbits. Antibodies were kept frozen at a stock concentration of 0.6 mg per mL (P2Y 1 , P2Y 2 ) and 0.3 mg per mL (P2Y 4 ). PCNA( monoclonal anti-proliferating cell nuclear antigen, clone PC10, raised in mouse ascites £uid; Sigma, Poole, UK) is a marker for proliferation (Miyagawa et al, 1989) . Active caspase-3 is part of the apoptotic machinery of the cell and is expressed in terminally di¡erentiating keratinocytes (Weil et al, 1999) . Active caspase-3 (Abcam, Cambridge, UK) antibody was raised in rabbit.
Immunohistochemical methods for frozen sections For immunostaining of cryostat sections, the avidin^biotin technique was used according to a revised protocol (Llewellyn-Smith et al, 1993) . Airdried sections were ¢xed for 2 min in 4% formaldehyde in 0.1 M phosphate bu¡er, containing 0.2% of a saturated solution of picric acid (pH 7.4). Endogenous peroxidase was blocked for 10 min with 50% methanol containing 0.4% hydrogen peroxide. Nonspeci¢c binding sites were blocked by a 20 min preincubation in 10% normal horse serum in 0.1 M phosphate bu¡er, containing 0.05% merthiolate (Sigma), followed by incubation with the primary antibodies diluted to 1:100 or 1:200 in antibody diluent (10% normal horse serum in PBS þ 2.5% sodium chloride (NaCl) at 41C overnight. Subsequently, the sections were incubated with biotinylated donkey anti-rabbit IgG (Jackson ImmunoResearch Laboratory, West Grove, Pennsylvania) diluted to 1:500 in 1% normal horse serum in PBS for 30 min, followed by ExtrAvidin peroxidase conjugate (Sigma) diluted to 1:1000 in PBS for 30 min at room temperature. After a wash step, a nickel-diaminobenzidine enhancement technique was used to visualize the reaction product. Sections were washed three times with PBS after each of the above steps except after preincubation with 10% normal horse serum. After the last wash, sections were dehydrated twice in isopropanol and mounted with EUKITT (BDH Laboratory Supplies, Poole, UK).
Controls for immunohistochemical method in frozen sections
Control experiments were carried out with primary antibodies omitted from the staining procedure or the primary antibodies preabsorbed with the corresponding peptides.
Double labeling of P2X 7 receptor antibody with either terminal deoxynucleotidyl transferase-mediated deoxyuridine triphosphate nick end-labeling (TUNEL) or anti-human caspase 3 TUNEL was performed using a kit (Boehringer Mannheim, Germany). TUNEL identi¢es cells undergoing apoptosis by labeling nuclear DNA fragments that have been cleaved during apoptosis (Gavrieli et al, 1992) . Sections were ¢xed and incubated with the P2X 7 receptor antibody overnight as described above. Then either the TUNEL or the anti-caspase 3 protocol were followed.
For double labeling with TUNEL, sections were washed in PBS and then incubated with the TUNEL reaction mixture for 1 h at 371C; then for 1 h with biotinylated donkey anti-rabbit antibody at a concentration of 1:500; then for 1 h with streptavidin Texas red (Amersham International Plc, Amersham, UK) at a concentration of 1:200. Sections were washed three times with PBS after each of the above steps and at the end of the staining procedure mounted in Citi£uor (Citi£uor Ltd, Leicester, UK).
For double labeling with anti-caspase-3, sections were washed in PBS and then were incubated with biotinylated donkey anti-rabbit IgG (Jackson ImmunoResearch Laboratory) diluted to 1:500 in 1% normal horse serum in PBS for 1 h, followed by ExtrAvidin peroxidase conjugate (Sigma) diluted to 1:1500 in PBS for 1 h, tyramide ampli¢cation for 8 min (Tyramide Ampli¢cation Kit, NEN Life Science Products, Boston, Massachusetts) and then streptavidin Texas red, diluted 1:200 in PBSmerthiolate for 10 min. Sections were washed three times in PBS after each of the above steps. Sections were preincubated for 20 min in 10% normal goat serum and then incubated at room temperature for 2 h with rabbit anti-human active caspase-3 (Abcam). Sections were washed and incubated with the directly labeled secondary antibody, Oregon-greenlabeled goat-anti-rabbit IgG (Jackson ImmunoResearch Laboratory), diluted 1:100 for 45 min. Sections were washed and mounted in Citi£uor. Double labeling of P2Y 2 receptor antibody with PCNA Sections were ¢xed and incubated with P2Y 2 antibody diluted 1:100 overnight as described above. After a wash step, biotinylated donkey anti-rabbit IgG antibody, diluted 1:500 in 1% normal horse serum in PBS, was then applied for 1 h followed by streptavidin Texas red, diluted 1:200 in PBSmerthiolate for 1 h at room temperature. Sections were preincubated for 30 min with 10% normal goat serum diluted in 0.1 M phosphate bu¡er, containing 0.05% merthiolate (Sigma), and then incubated for 2 h at room temperature with PCNA antibody (monoclonal anti-proliferating cell nuclear antigen, clone PC10, raised in mouse ascites £uid; Sigma) diluted 1:1000. After a wash step, the directly labeled secondary antibody goat anti-mouse £uorescein isothiocyanate (Nordic Immunological Laboratories, Tilburg, the Netherlands) was applied at a dilution of 1:200 for 1 h and then sections were washed and mounted in Citi£uor.
Immunohistochemical method for para⁄n sections The method below was an adaptation of the routine method used for immunohistochemistry in para⁄n sections at The RAFT Institute, Mount Vernon Hospital, Northwood (Middlesex, UK) and was developed by Elizabeth Clayton, Histology Department, RAFT. Microwave antigen retrieval was used for the visualization of both P2X 5 and P2X 7 receptors in para⁄n sections. Para⁄n blocks were sectioned at 4 mm on a Reichert-Jung Microtome, and sections were taken on Snowcoat Extra slides (Surgipath, St Neots, Cambs, UK). The slides were then dried in an oven for 2 h at 601C. P2X 7 receptors were demonstrated using a routine streptavidin alkaline phosphatase method and a Vector Red ¢nal substrate system (Vector Laboratories, Peterborough, UK). P2X 5 receptors were demonstrated via tyramide ampli¢cation and a nickeldiaminobenzidine ¢nal substrate system.
All histologic solvents, bu¡ered formal saline, toluene, xylene and alcohol were supplied by Genta Medical (York, UK). Sections were dewaxed and rehydrated using xylene and graded concentrations of industrial methylated spirits, then washed in running tap water for 5 min Sections were microwaved (Daewoo 800 W domestic microwave) at full power in a plastic rack for 10 min in a covered but not closed container ¢lled with 400 mL 1 mM ethylenediamine tetraacetic acid at pH 8.0 and then immediately washed in cold tap water for 2 to 3 min.
Sections were ringed with a wax pen and placed in a humidi¢cation chamber for the application of immunoreagents. After incubation with each immunoreagent, all slides were rinsed o¡ with a wash bottle ¢lled with Tris-bu¡ered saline (TBS) containing Tween 20 (two drops Tween per 500 mL of TBS) (TBS þ T), placed in a slide rack and put in a fresh bath of TBS þ T on a magnetic stirrer for 15 min. This step was crucial in order to reduce background staining.
Method for P2X 5 receptor antibody immunostaining in para⁄n sections Endogenous peroxidases were blocked using a 3% hydrogen peroxide solution in methanol containing 0.3% sodium azide for 30 min. Sections were washed in running tap water for 2 to 3 min and then placed in a bath of 50 mM TBS (50 mM Tris þ 150 mM NaCl pH 7.6). Sections were incubated with one drop of Avidin D blocking solution for 15 min (Avidin Biotin Blocking Kit SP200, Vector Laboratories). This was then £icked o¡ and rinsed with TBS þ T. One drop of the Biotin blocking solution was then applied for 15 min (Avidin Biotin Blocking Kit SP200, Vector Laboratories). Sections were washed with TBS þ T and 100 mL 1:5 normal swine serum diluted in DAKO ChemMate antibody diluent (DAKO S2022, DAKO, Ely, UK) was then applied to each section for 30 min. Excess swine serum was £icked o¡ the slides and the primary P2X 5 receptor antibody (diluted 1:600 in DAKO ChemMate diluent) was applied for 15 min.
The DAKO CSA kit was used for all subsequent layers as per kit instructions (DAKO Catalyzed Serum Ampli¢cation system K1500 with biotinylated anti-rabbit secondary antibody (DAKO K1498); DAKO). After primary antibody incubation and washing, sections were incubated with 100 mL biotinylated anti-rabbit antibody (prediluted from the kit) for 15 min (solution 4). After washing with TBS þ T, 100 mL of avidinb iotin complex solution (prepared 30 min prior to use (solutions 5^7)) was applied for 15 min. After washing with TBS þ T, 100 mL of tyramide ampli¢cation solution was applied for 15 min (solution 8). After a wash step with TBS þ T, 100 mL of streptavidin-peroxidase reagent was applied for 15 min (solution 9). Following washing with TBS þ T, the nickeldiaminobenzidine substrate chromogen was applied for 5 min. P2X 5 receptors appeared brown and the intensity of the chromogen was checked under the microscope before washing slides in running tap water.
Method for P2X 7 receptor antibody immunostaining in para⁄n sections The streptavidin alkaline phosphatase method was used to demonstrate P2X 7 receptors in para⁄n sections. This method provided staining with a striking contrast for positive and negative reactions, was £uorescent when looking for low level expression and caused no confusion with endogenous pigments.
Endogenous alkaline phosphatase was blocked by a 20 min incubation in a bath of 20% acetic acid solution. Sections were washed and incubated ¢rst with avidin D blocking solution (Vector Laboratories), then biotin blocking solution (Vector Laboratories), and then 1:5 normal swine serum as above. One hundred microliters of P2X 7 receptor antibody, diluted 1:100 was applied for 1 h at room temperature or overnight at 41C.
After a wash step with TBS þ T, 100 mL of biotinylated anti-rabbit antibody (DAKO E0353), diluted 1:200 in DAKO ChemMate diluent (DAKO), was applied for 30 min. After washing in TBS þ T, 100 mL of streptavidin alkaline phosphatase (Vector SA5100) diluted 1:200 in DAKO ChemMate diluent, was applied for 30 min After washing in TBS þ T, Vector Red substrate (Vector Alkaline phosphatase substrate, SK5100) made up in 200 mM Tris^HCl (pH 8.2) was applied for 10 min. P2X 7 receptor staining appeared bright pink, the intensity of the chromogen was checked under the microscope prior to washing the slides in running tap water for 2 to 3 min.
Counterstaining Nuclei were counterstained blue with Harris hematoxylin for 10 to 30 s and all sections were subsequently dehydrated, cleared, and mounted.
Controls for immunohistochemical method in para⁄n sections Negative controls were used: either diluent only or 1:5 normal swine serum were substituted for the P2X 5 or P2X 7 receptor antibody at an equivalent dilution. Numerous test sections showed no reaction with either the diluent alone or with the added normal swine serum; therefore, subsequently, the ChemMate diluent was used alone as a negative control.
Photography The results were analyzed using a Zeiss Axioplan high de¢nition light microscope (Oberkochen, Germany) mounted with a Leica DC 200 digital camera (Heerbrugg, Switzerland).
A431 cell line This human epidermal SCC cell line was purchased from the European Collection of Cell Cultures (ECACC no. 85090402). Cells were grown at 371C in a humidi¢ed 5% CO 2 atmosphere. Cultures were grown on plastic in Dulbecco minimal Eagle's medium supplemented with 10% fetal calf serum, penicillin, streptomycin, and L-glutamine. Cells were disaggregated at 70% con£uency with trypsin/ethylenediamine tetraacetic acid and seeded at 1 Â 10 4 cells per well in a 96 well plate. This seeding density gave the best growth curve over a 72 h period.
Proliferation assay Twenty-four hours after seeding into 96 well plates, medium was gently aspirated from culture wells and P2 receptor subtype agonists were applied to the A431 cells, diluted in medium. These were obtained from Sigma and included: ATP; uridine 5 0 -triphosphate (UTP), P2Y 2 receptor agonist (von Kˇgelgen and Wetter, 2000); adenosine 5 0 -O-(3 -thiotriphosphate) (ATPgS), P2X 5 receptor agonist (Khakh et al, 2000) ; 2 0 -3 0 -O-(4 -benzoyl-benzoyl) adenosine 5 0 -triphosphate (BzATP), P2X 7 receptor agonist (Khakh et al, 2001a) ; and 2-methylthioadenosine 5 0 -diphosphate (2MeSADP), P2Y 1 receptor agonist (von Kˇgelgen and Wetter, 2000) . The pH of the drug solutions prepared in the culture medium was 7.0.
Changes in cell number were quanti¢ed via a colorimetric assay using crystal violet (Gillies et al, 1986; Kueng et al, 1989) and read using a spectrophotometric plate reader (Model 550, Microplate Manager 4.0 BioRad Laboratories, Inc. Hercules, CA USA) at 0, 24, 48, and 72 h after addition of drugs. For the colorimetric assay, a solution of 0.5 g crystal violet, 0.85 g NaCl, 5 mL 10% formal saline, 50 mL absolute ethanol, 45 mL distilled H 2 O was used. Medium was gently aspirated from wells of a 96 well plate and 100 mL of the colorimetric assay mixture was added to each well and incubated at room temperature for 10 min. This mixture allowed simultaneous ¢xation of cells and penetration of the crystal violet dye into the cells. After washing three times in PBS, 33% acetic acid was used to elute color from cells and optical density was read at 595 nm using the spectrophotometric plate reader. The changes in cell number identi¢ed by the crystal violet assay were validated at least once for each drug set by doing actual cell counts with a hemocytometer. To con¢rm that the optical density of the wells correlated with cell numbers, a control assay was performed for each experiment, where known numbers of cells were seeded in ascending seeding densities and the plate read as soon as cells had attached. Cell number versus optical density was plotted. The R 2 value of the trend line was always greater than 0.98 (data not shown).
Statistical analysis Each proliferation assay experiment was repeated an average of eight times, each with triplicate samples. Data analysis was performed using Microsoft Excel 97 and GraphPad Prism 3.0 software. One-way analysis of variance (ANOVA) and Bonferroni's multiple comparison test were carried out between groups.
RESULTS
P2X 5 , P2X 7 , P2Y 1 , P2Y 2 , and P2Y 4 receptors were expressed in frozen sections of BCC P2X 5 receptors were heavily expressed in tumor cells of BCC, but slightly less heavily than in the epidermis (Fig 1a) . At high power, P2X 5 receptors were expressed within the cell cytoplasm of tumor cells and the level of staining intensity in tumor cells was comparable with that seen P2 RECEPTORS IN NONMELANOMA SKIN CANCER 317 in basal cells within the epidermis. In the central area of the tumor, staining was absent (Fig 1a) . P2X 7 receptors were expressed in the necrotic center of nodular BCC (Fig 1b) . Although nonspeci¢c staining in necrotic areas does occur, this staining disappeared on preabsorption of the P2X 7 primary antibody, suggesting that it was speci¢c. At higher magni¢cation, the staining was seen to be associated with mast cells, macrophages, and swollen ¢broblasts in the stroma surrounding the tumor. In normal skin, P2X 7 receptors are found in the stratum corneum. It was noticeable that in the more normal areas of skin that P2X 7 receptors were present, but in the area immediately over the BCC, the expression of P2X 7 receptors disappeared (Fig 1c) .
P2Y 1 receptors were expressed in the stroma surrounding the tumor, but not within the tumor cells (Fig 1d) . P2Y 2 receptors (Fig 1e) and P2Y 4 receptors (Fig 1f) were expressed within the tumor but not in the surrounding stromal matrix. Both the omission of the primary antibody and preabsorption with corresponding peptides were performed as controls in sections of BCC. There was no immunoreaction when the primary antibody was omitted. The immunoreaction was abolished after preabsorption of the P2X 5 (Fig 1g) , P2X 7 (Fig 1h) , P2Y 1 (Fig 1i) , P2Y 2 (Fig 1j) , and P2Y 4 receptor antibodies (Fig 1k) with the corresponding peptides, con¢rming the speci¢city of the immunoreaction.
P2X 5 , P2X 7 , P2Y 1 , and P2Y 2 receptors were expressed in frozen sections of SCC P2X 5 receptors were more heavily expressed in the tumor cells than in the cells of the surrounding epidermis and P2X 5 receptors were located speci¢cally on the cell (c) P2X 7 receptors were found in the stratum corneum in the more normal areas of skin (arrows), but in the area immediately over the BCC, the expression of P2X 7 receptors disappeared. Scale bar ¼ 175 mm. (d) P2Y 1 receptors were expressed in the basal layer of the epidermis (arrow) overlying the tumor, and in the stroma (S) surrounding the tumor (T), but not within the tumor itself. Scale bar ¼ 100 mm. (e) P2Y 2 receptors were expressed in the basal layer of the epidermis (arrow), and within tumor (T) and not in the surrounding stromal matrix (S). There was some nuclear staining within the epidermis Scale bar ¼ 100 mm. (f) P2Y 4 receptors were faintly expressed in the basal layer of the epidermis (arrow), and more strongly within tumor (T) and not in the surrounding stromal matrix (S). There was some nuclear staining within the epidermis. Scale bar ¼ 100 mm. The immunoreaction was abolished after preabsorption of the (g) P2X 5 , (h) P2X 7 , (i) P2Y 1 , (j) P2Y 2 , and (k) P2Y 4 receptor antibodies with the corresponding peptides, con¢rming the speci¢city of the immunoreaction. There was, however, some melanin in the basal layer of the epidermis, which could be distinguished from immunostaining by its color. Scale bars: (g^k) 250 mm. membrane of the SCC cells (Fig 2a) , rather than within the cell cytoplasm as in BCC tumor cells. P2X 7 receptors were strongly expressed in the stratum corneum of the epidermis but only weakly expressed in the nucleus of occasional tumor cells (Fig 2b) . P2Y 1 receptors were strongly expressed within the stromal matrix surrounding the tumor nests within the dermis, but not expressed within the tumor (Fig 2c) . P2Y 2 receptors were strongly expressed within the tumor, but not expressed within the surrounding stromal matrix (Fig 2d) . The P2Y 2 receptor staining appears to be both in the cell membrane and weakly in the nucleus of the tumor cells. The SCC cells appear nonuniform in size and shape, with vacuolation of the cytoplasm in some cells, which may explain the nonuniformity of P2Y 2 staining in some tumor cells. P2Y 4 receptors were not expressed in the SCC'S examined.
Both the omission of the primary antibody and preabsorption with corresponding peptides were performed as controls in sections of SCC. There was no immunoreaction when the primary antibody was omitted. The immunoreaction was abolished after preabsorption of the P2X 5 (Fig 2e) , P2X 7 (Fig 2f) , P2Y 1 (Fig 2g) , and P2Y 2 receptor antibodies (Fig 2h) with the corresponding peptides, con¢rming the speci¢city of the immunoreaction. The distribution of P2X and P2Y receptors in both BCC and SCC is summarized in Table I . P2 receptor staining in normal skin is described in detail in Greig et al (2003) .
Double labeling of P2X 7 receptors with TUNEL or antihuman caspase-3 showed colocalization, and double labeling of P2Y 2 receptors with PCNA showed overlap in NMSC Double labeling of P2X 7 receptors and TUNEL in the center of a nodular BCC showed colocalization on cells undergoing apoptosis, with P2X 7 receptors also expressed in cellular fragments (Fig 3a) . Double labeling with P2X 7 receptors and anti-human caspase-3, showed colocalization in the nuclei of cells within the tumor nests of a SCC (Fig 3b) . Double labeling with P2Y 2 receptors (red) and PCNA (green) (Fig 3c) showed that there was much proliferative activity within SCC tumor nests and that there was overlap between the cells expressing PCNA and P2Y 2 receptors. P2X 5 and P2X 7 receptors were expressed in para⁄n sections of BCC and SCC The immunostaining of para⁄n sections showed essentially the same distribution as that in frozen sections, although more detail of the cellular and subcellular composition was visible. The development of this method also allowed us to look at archive material of para⁄n sections of di¡erent tumor subtypes. P2X 5 and P2X 7 receptors were examined because they are involved in early keratinocyte di¡erentiation and terminal keratinocyte di¡erentiation/ apoptosis, respectively. Para⁄n sections of BCC were grouped as follows: 11 nodular (including three solid subtypes), nine super¢cial multifocal, and 24 in¢ltrative (morpheic). Of the 24 in¢ltrative BCC, seven represented a subgroup of ''horrifying BCC'' (Horlock et al, 1998) , which were clinically locally aggressive and deeply invasive. The distribution of P2X 5 and P2X 7 receptors within subgroups of BCC is summarized in Table II .
In nodular BCC, P2X 5 receptor staining (brown) was present both in the tumor (in the cell cytoplasm), but also in cells of the surrounding stromal matrix (Fig 4a) . These positive stromal cells were likely to be endothelial cells, seen at higher power in association with capillaries. P2X 7 receptors (pink) were (c) P2Y 1 receptors were strongly expressed within the stromal matrix (S) surrounding the nests of tumor (T) within the dermis, but not expressed within the tumor itself. Scale bar ¼ 50 mm. (d) P2Y 2 receptors were strongly expressed within the tumor (T) within the dermis, but not expressed within the surrounding stromal matrix (S). Scale bar ¼ 50 mm. The immunoreaction was abolished after preabsorption of the (e) P2X 5 , (f) P2X 7 , (g) P2Y 1 , and (h) P2Y 2 receptor antibodies with the corresponding peptides, con¢rming the speci¢city of the immunoreaction.Scale bars: (g^j) 200 mm.
expressed in the necrotic center of nodular BCC (Fig 4b) the same as in frozen sections. In super¢cial multifocal BCC, P2X 5 receptors were expressed in a patchy fashion throughout tumor nests mostly in the tumor cell cytoplasm (Fig 4c) . P2X 7 receptors were weakly expressed in the nucleus of occasional tumor cells (Fig 4d) . In in¢ltrative BCC, the P2X 5 receptor staining was di¡erent in cells at the edge of the tumor nest, from cells in the center (Fig 4e) . Cells at the edge had positive staining in the plasma membrane, and this staining appeared to be polarized to the surface of the cells that were in contact with the basement membrane surrounding the tumor nest. In contrast, cells in the center of the tumor nest had positive staining for P2X 5 receptors in the cell cytoplasm, as seen in nodular (Fig 4a) and super¢cial multifocal BCC (Fig 4c) . P2X 7 receptor immunoreactivity in in¢ltrative BCC was mainly in shrunken, condensed, possibly apoptotic nuclei near the center of tumor nests (Fig 4f) . In ''horrifying BCC'' , a locally aggressive and deeply invasive subgroup of in¢ltrative BCC, P2X 5 receptors were seen in the cytoplasm of tumor cells in association with numerous cells undergoing mitosis (Fig 4g) . In ''horrifying BCC'' , P2X 7 receptors were expressed in the nucleus of numerous cells but unlike in in¢ltrative BCC the nuclei were not condensed or apoptotic (Fig 4h) . SCC were subclassi¢ed as follows: ¢ve Bowen's disease (carcinomas in situ), four di¡erentiated SCC, and ¢ve invasive SCC. Two basisquamous (metaplastic) carcinomas, showing characteristics of both BCC and SCC, were also analyzed immunohistochemically. The distribution of P2X 5 and P2X 7 receptors within subgroups of SCC is summarized in Table III .
All examples of Bowen's disease (SCC in situ) examined were positive for P2X 5 receptors ( Table III) . The staining was mainly in the cytoplasm and was much more intense than in the surrounding normal epidermis (Fig 5a) . There were also positive cells staining for P2X 5 receptors within the dermis (Fig 5a) , which were likely to be endothelial cells in association with capillaries. P2X 7 receptors were expressed in Civatte bodies (apoptotic keratinocytes) within the tumor (Fig 5b) . All four well-di¡erentiated SCC were positive for both P2X 5 and P2X 7 receptors (Table III) . In well-di¡erentiated SCC, P2X 5 receptors were heavily expressed throughout the tumor, in the tumor cell cytoplasm (Fig 5c) . P2X 5 receptors were heavily expressed at the edges of keratin pearls, but were less intensely expressed in the more di¡erentiated central areas of keratin pearls. In contrast, P2X 7 receptors were only expressed in the center of keratin (h) P2X 7 receptors (pink) were expressed in the nucleus of numerous cells (arrows) but unlike in¢ltrative BCC (f) the nuclei were not condensed. Scale bar ¼ 25 mm.
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pearls in more di¡erentiated cells and in areas where necrosis had occurred (Fig 5d) . In invasive SCC, P2X 5 receptors were more heavily expressed in the invasive tumor compared with normal areas of epidermis (Fig 5e) . In invasive SCC, P2X 7 receptor immunoreactivity was seen within shrunken, pyknotic, apoptotic-looking nuclei, often in cells towards the center of a tumor nest (Fig 5f) . In basisquamous (metaplastic) carcinomas, P2X 5 receptor labeling was found both in the tumor cell (Fig 5g) . P2X 7 receptors were expressed in condensed nuclei, which were possibly apoptotic (Fig 5h) . Both basisquamous carcinomas examined were positive for P2X 5 and P2X 7 receptors (Table III) .
P2X 5 , P2X 7 , P2Y 1 , and P2Y 2 receptors were expressed in A431 cells grown in culture P2X 5 (Fig 6a) , P2X 7 (Fig 6b) , P2Y 1 (Fig 6c) , and P2Y 2 receptors (Fig 6d) were expressed on A431 cells on the cell membranes. Both the omission of the primary antibody and preabsorption with corresponding peptides were performed as controls. There was no immunoreaction when the primary antibody was omitted. Furthermore, the immunoreaction was abolished after preabsorption of the P2X 5 , P2X 7 , P2Y 1 , and P2Y 2 receptor antibodies with the corresponding peptides, con¢rming the speci¢city of the immunoreaction.
Actions of P2 receptors agonists on cell numbers of cultured cutaneous SCC, A431 cells Low concentrations of ATP (10 mM) caused an increase in cell number, whereas high concentrations of ATP (500^5000 mM) caused a signi¢cant decrease (po0.001) in cell number at 48 h after application (Fig  7) , with cells in the 5000 mM ATP solution appearing rounded up and dead (Fig 7e) . Low concentrations of ATPgS (1^10 mM) and high concentrations of UTP (1000 mM) caused an increase in cell number, with UTP causing a signi¢cant e¡ect (po0.001). High concentrations of ATP (500 mM) and ATPgS (100^500 mM) caused a signi¢cant decrease (po0.001) in cell number, at 48 h after drug application to A431 cells (Fig 8a) . The P2X 7 receptor agonist, BzATP (500 mM) (Fig 8b) caused a signi¢cant reduction in cell number (po0.001) and the P2Y 1 receptor agonist, 2MeSADP (1^500 mM) (Fig 8c) caused a reduction in cell number, which was not statistically signi¢cant.
DISCUSSION
In this study, we have obtained the ¢rst direct evidence for the expression of P2X 5 , P2X 7 , P2Y 1 , and P2Y 2 receptors in human BCC and SCC, using immunohistochemistry and functional studies in vitro with the human SCC, A431 cell line. In vitro experiments with A431 cells were used to give an indication of the e¡ects of P2 receptor agonists on SCC cells in vivo, but further experiments are needed to assess the e¡ects in tumors. Low concentrations of ATP increased A431 cell number. Previous work with A431 cells has shown that micromolar range concentrations of ATP are mitogenic for A431 cells (Huang et al, 1989) and increase intracellular calcium levels (Gonzalez et al, 1988) . ATP has also been shown to activate cell proliferation in human ovarian tumor cells (Popper and Batra, 1993) and in MCF-7 breast cancer cells (Dixon et al, 1997) . From our functional data in A431 cells, UTP, the P2Y 2 receptor agonist caused a signi¢cant increase (po0.001) in proliferation. P2Y 2 receptors were heavily expressed in both BCC and SCC and there was overlap between cells expressing PCNA and P2Y 2 receptors. The proportion of PCNApositive cells in SCC tumor nests was higher than in normal epidermis. Where this increased expression of PCNA was found, so the expression of P2Y 2 receptors was proportionally increased compared with normal epidermis. Taken together, the PCNA ¢ndings further con¢rm our ¢ndings in the functional experiments that P2Y 2 receptors are likely to be involved in proliferation. Previous work has localized P2Y 2 receptor mRNA in human epidermal basal cells via in situ hybridization (Dixon et al, 1999) . UTP has also been shown to cause proliferation of normal keratinocytes (Dixon et al, 1999) and HaCaT cells (Lee et al, 2001) . Functional P2Y 2 receptors have also been characterized on human ovarian cancer cells (Schultze-Mogasu et al, 2000) , colorectal carcinoma cells (H˛pfner et al, 1998) , prostate carcinoma cells (Janssens and Boeynaems, 2001 ), endometrial cancer cell lines (Katzur et al, 1999) , and MCF-7 breast cancer cells (Wagsta¡ et al, 2000) .
In contrast, high concentrations of ATP and the P2X 7 receptor agonist, BzATP caused a signi¢cant decrease in A431 cell number (po0.001). The concentrations of ATP used were anticipated to be within the physiologic range because ATP physiologically released from nerves (Sperla¤ gh and Vizi, 1996) , endothelial cells (Bodin and Burnstock, 1998) , and urothelial cells (Ferguson, 1999) can reach very high levels extracellularly (4 10^3 mM) before being broken down by ectoenzymes. P2X 7 receptors were heavily expressed in the necrotic center of nodular BCC and colocalized with TUNEL labeling. They were also expressed in apoptotic cells in both in¢ltrative BCC and in SCC and P2X 7 receptors colocalized with active caspase-3. The P2X 7 receptor is unlike other P2X receptors because it is a bifunctional molecule that can be triggered by low concentrations of ATP to act as a channel permeable to small cations, or at high concentrations (4 100 mM), forms a cytolytic pore permeable to large hydrophilic molecules up to 900 Da (Surprenant et al, 1996) . The opening of this pore results in the increase in intracellular cytosolic free calcium ions, leading to cell death. The reduction in A431 cell Figure 7 . Change in cell number of SCC, A431 cells at 48 h after ATP application. At 48 h after application, low doses of ATP (10 mM) caused an increase in cell number, whereas high doses of ATP (1000^5000 mM) (po0.001) caused a signi¢cant decrease. Results represent the mean of 26 experiments. npo0.001 compared with control. Error bars represent mean 7 SEM. These e¡ects were shown also by the colony size and cell morphology. A431 cells were stained with crystal violet and phase contrast micrographs were taken. (a) Controlöcells grown in A431 medium only; (b) 10 mM ATP caused colonies of A431 cells to appear visibly larger than in control wells; (c) 100 mM ATP caused no change in the colony size; (d) 1000 mM ATP and (e) 5000 mM ATP both caused a marked decrease in colony size, with cells rounding up and dying in 5000 mM ATP. Scale bar ¼ 150 mm.
number with increasing concentrations of ATP or BzATP could have resulted from either inhibition of proliferation or stimulation of cell death; however, BzATP is established as a 10 to 30 times more potent agonist at P2X 7 receptors than ATP, leading to apoptosis (North, 2002) . There is no published evidence that P2X 7 receptors mediate inhibition of cell proliferation.
The P2X 7 receptor is involved in the release of interleukin-1b (Ferrari et al, 1997) and the induction of cell death (Zheng et al, 1991; Ferrari et al, 1996) . P2X 7 receptors have been localized in rat and human epidermis (Gr˛schel-Stewart et al, 1999; Greig et al, 2003) and are also found on dendritic cells, macrophages, and microglial cells, where high concentrations of extracellular ATP can trigger apoptosis via these receptors and there is increasing evidence that this process is dependent on the caspase signaling cascade (Coutinho-Silva et al, 1999; Ferrari et al, 1999) . Extracellular ATP induces apoptosis and inhibits growth of colorectal carcinoma cells in culture (H˛pfner et al, 1999) . ATP inhibits growth in breast cancer cells (Spungin and Friedberg, 1993) , androgen-independent prostate carcinoma cells (Fang et al, 1992) , and Ehrlich tumor cells (Lasso de la Vega et al, 1994) .
BCC are slow-growing tumors with paradoxically high proliferative activity. The slow growth has been previously explained by a concurrent high apoptotic activity (Miller, 1991a, b) . The interpretation of BCC as a neoplasm with high apoptotic activity has been supported by electron microscopy (Miller, 1991a, b) and an end-labeling study (Mooney et al, 1995) . From our analysis of di¡erent subgroups of BCC in para⁄n section, it appears that in moderately aggressive tumors, there is a high level of expression of P2X 7 receptors, but with increasing aggressiveness of tumor, this is reduced. The 24 in¢ltrative BCC studied can be divided into two groups: 17 in¢ltrative BCC and seven ''horrifying BCC'' . In 17 in¢ltrative BCC, 59% expressed P2X 7 receptors but only 14% of ''horrifying BCC'' expressed P2X 7 receptors and within this tumor, the receptor was expressed on most of the cells within it, with positive cells not appearing to be apoptotic, in contrast to the other group of in¢ltrative BCC analyzed. Reduced apoptosis may lead to unstable tissue kinetics, favoring an increase in total cell numbers, which in tumors correspond to the stage of cellular expansion. A reduction in apoptosis may be responsible for the preservation of genetically aberrant cells, favoring neoplastic progression (Staibano et al, 1999) . This may partly explain the aggressive nature of these ''horrifying BCC'' . Analysis of para⁄n sections of SCC showed that P2X 7 receptors were expressed in all the di¡erentiated tumors studied, but in only three of ¢ve invasive SCC. This would suggest, despite the small sample size that more aggressive tumors also have reduced expression of P2X 7 receptors.
High concentrations of ATPgS, a potent P2X 5 receptor agonist, caused a signi¢cant decrease in cell number, at 48 h after drug application to A431 cells. This may be because cells are withdrawing from the cell cycle and di¡erentiating. There is evidence from other tissues regarding the role of P2X 5 receptors. In normal rat and human epidermis (Greig et al, 2003) P2X 5 receptors are found predominantly in di¡erentiating keratinocytes (Gr˛schel-Stewart et al, 1999) . In fetal rat skeletal muscle, P2X 5 receptors are sequentially expressed during development (Ryten et al, 2001 ). P2X 5 receptors have been implicated in the regulation of osteoblastic di¡erentiation and proliferation (Hoebertz et al, 2000) and in triggering the di¡erentiation of skeletal muscle satellite cells (Ryten et al, 2002) . In para⁄n sections of SCC, P2X 5 receptors were highly expressed in all subgroups of tumors, with increased expression compared with the surrounding ''normal'' epidermis. P2X 5 receptors were not found in the basal layer in Bowen's disease (carcinoma in situ), but only in the suprabasal, di¡erentiated cell layers. P2X 5 receptor staining in SCC was on the cell membrane, whereas in BCC, the receptors were expressed in the cell cytoplasm. In basisquamous (metaplastic) carcinomas, P2X 5 receptor labeling was found both in the tumor cell membrane and within the cytoplasm, re£ecting the dual di¡erentia-tion of this tumor subtype. The cytoplasmic distribution and Figure 8 . Comparison of e¡ect of P2 agonists at 48 h after drug application to A431 cells. (a) At 48 h after application, ATP (1^10 mM), ATPgS (1^10 mM), and UTP (1000 mM) (po0.001) caused an increase in cell number of primary human keratinocyte cultures, whereas ATPgS (100^500 mM) (po0.001) and ATP (500 mM) (po0.001) caused a signi¢cant decrease in cell number. Results represent the mean of eight experiments. n po0.001 compared with control. (b) BzATP (P2X 7 receptor subtype agonist) (500 mM) caused a signi¢cant reduction in cell number ( n po0.001). Results represent the mean of eight experiments. n po0.001 compared with control. (c) 2MeSADP (P2Y 1 receptor subtype agonist) (1^500 mM) caused a reduction in cell number, which was not signi¢cant. Results represent the mean of eight experiments. Error bars represent mean 7 SEM. level of staining intensity of P2X 5 receptors in BCC tumor cells was comparable with that seen in basal cells within the normal epidermis, which may re£ect the basal cell origin of these tumors. In this study, P2X 5 receptors were present either or both in the cell membrane and in the cytoplasm. Studies using P2X 2 receptors tagged with green £uorescent protein in hippocampal neurons have con¢rmed that P2X receptors can have both a cytoplasmic and cell membrane distribution (Khakh et al, 2001b) . P2X 1 receptors tagged with green £uorescent protein (Dutton et al, 2000; Li et al, 2000) and native P2X 1 receptors (Ennion and Evans, 2001 ) have also been shown to undergo internalization during application of ATP or ab-meATP to the cell. It has been proposed that P2X 1 receptor internalization is part of the cellular recycling of receptors and that it is part of the process of receptor activation, inactivation, internalization, and recovery (Ennion and Evans, 2001) . It is likely that P2X 5 receptors also take part in these processes and this is why they have been localized both on the cell membrane and in the cell cytoplasm.
In para⁄n sections of BCC, P2X 5 receptors were expressed on the majority of tumors; however, with increasing aggressiveness of tumor, the expression was reduced. Considering the two groups of in¢ltrative BCC: of 17 in¢ltrative BCC, 82% expressed P2X 5 receptors but only 57% of ''horrifying BCC'' expressed P2X 5 receptors. In P2X 5 receptor positive ''horrifying BCC'' , the receptor was expressed on most of the cells within it, in association with numerous cells undergoing mitosis, unlike the other group of in¢ltrative BCC analyzed, where P2X 5 receptor expression was more polarized towards the basement membrane and mitoses were few.
P2Y 1 receptors were expressed in the stroma surrounding both BCC and SCC, but not within the tumor cells. 2MeSADP, the P2Y 1 receptor subtype agonist, caused a reduction in A431 cell number, although this was not statistically signi¢cant. The actions of 2MeSADP might therefore be nonspeci¢c. It is known that for BCC to grow, they depend on interaction with their stromal matrix, and this is why it is generally thought that BCC are di⁄cult to establish in culture. It seems that P2Y 1 receptors do not have a direct proliferative role in A431 cells.
In summary, P2X 7 receptor immunostaining may be a useful histologic tool to assess apoptosis in tumors, with the loss of expression of the marker suggesting increased tumor aggressiveness. P2 purinergic receptor agonists alter A431 cell numbers via several mechanisms: UTP and low concentrations of ATP cause an increase in cell number via P2Y 2 receptors; ATPgS causes a decrease in cell number, probably because cells are lost from the cell cycle by being induced to di¡erentiate via activation of P2X 5 receptors; BzATP and high concentrations of ATP cause a signi¢-cant decrease in cell number via a direct e¡ect on P2X 7 receptors, which are known to be involved in mediating apoptosis. We have demonstrated that NMSC contain purinergic receptors and that these receptors are functional in A431 cells in vitro. This opens the pathway for new treatment modalities in these important skin cancers.
